Literature DB >> 3192180

Long-term follow-up of anti-HBe-positive chronic active hepatitis B.

G Fattovich1, L Brollo, A Alberti, P Pontisso, G Giustina, G Realdi.   

Abstract

Twenty-eight patients with chronic active hepatitis without cirrhosis who were positive for hepatitis B surface antigen and antibody to hepatitis B e antigen were followed for 1 to 15 years (mean 6.6 years) and underwent follow-up biopsy. At presentation, 12 of the 28 patients (43%) had hepatitis B virus DNA in serum, 10 (36%) had serologic evidence of hepatitis delta virus infection and 6 (21%) had no serologic markers of either hepatitis B virus replication or hepatitis delta virus infection. During follow-up, 15 (54%) patients developed active cirrhosis, including eight patients with hepatitis delta virus infection and five with hepatitis B virus DNA in serum. In seven (47%) of the 15 patients, cirrhosis developed within the first 2 years; all seven patients had bridging necrosis in the first liver biopsy, and five of these were infected with hepatitis delta virus. The remaining 13 (46%) patients did not develop cirrhosis during follow-up and showed either unchanged features of chronic active hepatitis (seven cases) or histologic improvement to chronic persistent hepatitis (five cases) or to normal liver (one case). In conclusion, the prognosis of anti-HBe-positive patients with chronic hepatitis B is poor, as 54% of the cases developed cirrhosis during a mean histologic follow-up period of 4.5 years, mainly in association with hepatitis delta virus infection or continuing hepatitis B virus replication.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3192180     DOI: 10.1002/hep.1840080630

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  19 in total

1.  Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B.

Authors:  L Zhuang; J You; B Z Tang; S Y Ding; K H Yan; D Peng; Y M Zhang; L Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

2.  Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine.

Authors:  R W King; S K Ladner; T J Miller; K Zaifert; R B Perni; S C Conway; M J Otto
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

3.  Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication.

Authors:  S K Ladner; M J Otto; C S Barker; K Zaifert; G H Wang; J T Guo; C Seeger; R W King
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 4.  Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B.

Authors:  Steven-Huy B Han
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection.

Authors:  F Zoulim; L Mimms; M Floreani; C Pichoud; I Chemin; A Kay; L Vitvitski; C Trepo
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

6.  HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines.

Authors:  J F Schlaak; G Tully; H F Löhr; G Gerken; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

7.  Natural history and prognostic factors for chronic hepatitis type B.

Authors:  G Fattovich; L Brollo; G Giustina; F Noventa; P Pontisso; A Alberti; G Realdi; A Ruol
Journal:  Gut       Date:  1991-03       Impact factor: 23.059

8.  A randomized, double-blind, controlled trial of natural interferon-beta therapy for e-antigen-negative chronic hepatitis B patients with abnormal transaminase levels.

Authors:  Y Arase; K Chayama; A Tsubota; N Murashima; Y Suzuki; I Koida; M Kobayashi; S Saitoh; K Ikeda; H Kumada; M Kobayashi; H Suzuki
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

9.  Characteristics of treatment naïve chronic hepatitis B in Bangladesh: younger populations are more affected; HBeAg-negatives are more advanced.

Authors:  Shanhinul Alam; Nooruddin Ahmad; Golam Mustafa; Khorshed Alam; Mobin Khan
Journal:  Saudi J Gastroenterol       Date:  2008-01       Impact factor: 2.485

Review 10.  A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection.

Authors:  Fabien Zoulim
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.